Research progress on therapeutic DC vaccine against melanoma
10.12206/j.issn.2097-2024.202211043
- VernacularTitle:治疗黑色素瘤的DC疫苗研究新进展
- Author:
Xinyue ZHANG
1
,
2
,
3
;
Zongguang TAI
4
;
Quangang ZHU
4
;
Zhongjian CHEN
4
;
Leilei BAO
1
,
3
Author Information
1. Jiangxi University of Chinese Medicine, Nanchang 330004 China
2. Shanghai Skin Disease Hospital, School of Medicine , Tongji University, Shanghai, 200443 China
3. Department of Pharmacy, Third Affiliated Hospital of Naval Medical University, Shanghai, 200438 China.
4. Shanghai Skin Disease Hospital, School of Medicine , Tongji University, Shanghai, 200443 China.
- Keywords:
melanoma;
therapeutic tumor vaccine;
dendritic cell;
immunotherapy
- From:
Journal of Pharmaceutical Practice
2023;41(11):643-647
- CountryChina
- Language:Chinese
-
Abstract:
Melanoma is the most aggressive skin malignant tumor, which is prone to early metastasis and relapse after treatment. Therapeutic tumor vaccines are new immunotherapies, which have the advantages of low toxicity and inhibiting tumor metastasis. Melanoma has a high mutation load and a large number of specific antigens. Currently, various types of tumor vaccines have been developed for melanoma, especially those based on dendritic cells (DC). Although the efficacy of therapeutic DC vaccines in melanoma has been confirmed by a number of studies, these vaccines still have problems such as insufficient immune effect and poor efficacy when used alone, and there is still a large room for improvement. In this paper, the current research status of therapeutic DC vaccines for melanoma was reviewed, and the research key points and optimization strategy of therapeutic DC tumor were prospected.
